Effectiveness of Taxanes Combined with Cisplatin and Fluorouracil for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

 ZHANGJian ¹ , ZHANGPing ² , YANGuo-Xin ¹

1. Department of Stomatology, The Second Hospital of Wuxi, Nanjing Medical University, Wuxi 214102, China;
2. School of Biotechnology, Jiangnan University, Wuxi 214122, China;

Corresponding author：

ZHANGJian, Email: zhangjian347@163.com

Keywords：

Taxanes; Cisplatin; Fluorouracil; Locally advanced head and neck squamous cell carcinoma; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20140056

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the effectiveness and safety of taxanes combined with cisplatin and fluorouracil (TFP) versus cisplatin and fluorouracil (FP) for locally advanced head and neck squamous cell carcinoma. Methods Databases such as The Cochrane Library (Issue 1, 2013), PubMed, EMbase, Web of Science, CBM, CNKI, VIP and WanFang Data were electronically searched to collect randomized controlled trials (RCTs) about taxanes combined with cisplatin and fluorouracil in the treatment of locally advanced head and neck squamous cell carcinoma from the date of their establishment to April 1^st, 2013. Two reviewers independently screened studies according to the inclusion and exclusion criteria, extracted data and evaluated the methodological quality of included studies. Then meta-analysis was performed using RevMan 5.2 software. Results A total of 7 RCTs involving 2 088 patients were included. The TFP group included 1 051 cases, while the FP group included 1 037 cases. The results of meta-analyses showed that, there were significant differences between the two groups in the 1-year, 2-year, and 3-year overall survival rates (RR=1.12, 95%CI 1.02 to 1.23, P=0.02; RR=1.20, 95%CI 1.11 to 1.29, P < 0.000 01; RR=1.18, 95%CI 1.07 to 1.31, P=0.000 7), the 1-year, 2-year, and 3 year of progressions free survival (RR=1.18, 95%CI 1.08 to 1.28, P=0.000 2; RR=1.20, 95%CI 1.06 to 1.36, P=0.003; RR=1.48, 95%CI 1.25 to 1.74, P < 0.000 01), the complete remission rate (RR=1.67, 95%CI 1.26 to 2.23, P=0.000 4), and the overall response to chemotherapy (RR=1.18, 95%CI 1.11 to 1.27, P < 0.000 01). As for the side effect, the FP group was superior to the TFP group in the neutropenia (RR=1.42, 95%CI 1.24 to 1.63, P < 0.000 01), alopecia (RR=16.09, 95%CI 4.59 to 56.38, P < 0.000 1), and febrile neutropenia (RR=2.21, 95%CI 1.29 to 3.80, P < 0.004). Conclusion The fluorouracil with cisplatin and fluorouracil for advanced head and neck squamous cell carcinoma might have better effects, but with higher side effects.

Citation： ZHANGJian, ZHANGPing, YANGuo-Xin. Effectiveness of Taxanes Combined with Cisplatin and Fluorouracil for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2014, 14(3): 327-334. doi: 10.7507/1672-2531.20140056 Copy

1.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. Cancer J Clin, 2005, 55(2):74-108.
2.	Seiwert TY, Cohen EE. State of the art management of locally advanced head and neck cancer. Br J Cancer, 2005, 92(8):1341-1348.
3.	Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase Ⅲ comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol, 2003, 21(1):92-98.
4.	Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol, 2004, 22(1):69-76.
5.	Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11:A phase Ⅲ trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol, 2006, 24(18 Suppl):5517.
6.	Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer:preliminary results of a European Organization for Research and Treatment of Cancer phase Ⅲ trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst, 1996, 88(13):890-899.
7.	Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma:Three meta-analyses of updated individual data. Lancet, 2000, 355(9208):949-955.
8.	Qin H, Luo J, Zhu YP, et al. Combination of Taxanes, Cisplatin and Fluorouracil as Induction Chemotherapy for Locally Advanced Head and Neck Cancer:A Meta-Analysis. PLoS ONE, 2012, 7(12):e51526.
9.	Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase Ⅲ study comparing Cisplatin plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol, 2005, 23(34):8636-8645.
10.	Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, Fluorouracil, and Docetaxel in unresectable head and neck cancer. N Engl J Med, 2007, 357(17):1695-1704.
11.	Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and Fluorouracil alone or with Docetaxel in head and neck cancer. N Engl J Med, 2007, 357(17):1705-1715.
12.	Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with Cisplatin and Fluorouracil alone or in combination with Docetaxel in locally advanced squamous-cell cancer of the head and neck:Long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol, 2011, 12(2):153-159.
13.	Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with Cisplatin and 5-Fluorouracil with or without Docetaxel for larynx preservation. J Natl Cancer Inst, 2009, 101(7):498-506.
14.	Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil(TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer:a phase Ⅱ randomized study. Ann Oncol, 2010, 21(7):1515-1522.
15.	Huang CE, Lu CH, Hen PT, et al. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer. J Clin Pharm Ther, 2012, 37(3), 342-347.
16.	Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available at:www.Cochrane-handbook.org.
17.	张质钢, 王小虎, 杨克虎, 等.奈达铂联合5-氟尿嘧啶治疗晚期食管癌的Meta分析.中国循证医学杂志, 2013, 13(1):39-46.
18.	Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma:three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet, 2000, 355(9208):949-955.
19.	Rinehart J, Ruff T, Cheung A, et al. Neo adjuvant and concomitant chemotherapy and radiation therapy in patients with advanced head and neck carcinoma. Otolaryngol Head Neck Surg, 2005, 132(1):69.
20.	Ruggeri EM, Carlini P, Pollera CF, et al. Long term survival in locally advanced oral cavity cancer:an analysis of patients treated with neoadjuvant cisplat in-based chemotherapy followed by surgery. Head Neck, 2005, 27(6):452-458.
21.	Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemo radiation:a new treatment paradigm. J Clin Oncol, 2006, 24(4):593-598.
22.	Guntinas-Lichius O, Appenrollts, Veelken F, et al. Phase Ⅱ study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope, 2006, 116(4):613-618.
23.	Chu DT, Sham JS, Au GK, et al. A phase study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasophryngeal carcinoma. Oral Oncol, 2005, 41(6):589-595.
24.	Francis PA, Kris MG, Rigas JR, et al. Paclitaxel(Taxol) and docetaxel(Taxotere):active chemotherapeutic agents in lung cancer. Lung Cancer, 1995, 12(1):163-172.
25.	Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-Ⅱ trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol, 2001, 19(4):1096-1104.

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. Cancer J Clin, 2005, 55(2):74-108.
2. Seiwert TY, Cohen EE. State of the art management of locally advanced head and neck cancer. Br J Cancer, 2005, 92(8):1341-1348.
3. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase Ⅲ comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol, 2003, 21(1):92-98.
4. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol, 2004, 22(1):69-76.
5. Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11:A phase Ⅲ trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol, 2006, 24(18 Suppl):5517.
6. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer:preliminary results of a European Organization for Research and Treatment of Cancer phase Ⅲ trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst, 1996, 88(13):890-899.
7. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma:Three meta-analyses of updated individual data. Lancet, 2000, 355(9208):949-955.
8. Qin H, Luo J, Zhu YP, et al. Combination of Taxanes, Cisplatin and Fluorouracil as Induction Chemotherapy for Locally Advanced Head and Neck Cancer:A Meta-Analysis. PLoS ONE, 2012, 7(12):e51526.
9. Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase Ⅲ study comparing Cisplatin plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol, 2005, 23(34):8636-8645.
10. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, Fluorouracil, and Docetaxel in unresectable head and neck cancer. N Engl J Med, 2007, 357(17):1695-1704.
11. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and Fluorouracil alone or with Docetaxel in head and neck cancer. N Engl J Med, 2007, 357(17):1705-1715.
12. Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with Cisplatin and Fluorouracil alone or in combination with Docetaxel in locally advanced squamous-cell cancer of the head and neck:Long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol, 2011, 12(2):153-159.
13. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with Cisplatin and 5-Fluorouracil with or without Docetaxel for larynx preservation. J Natl Cancer Inst, 2009, 101(7):498-506.
14. Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil(TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer:a phase Ⅱ randomized study. Ann Oncol, 2010, 21(7):1515-1522.
15. Huang CE, Lu CH, Hen PT, et al. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer. J Clin Pharm Ther, 2012, 37(3), 342-347.
16. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available at:www.Cochrane-handbook.org.
17. 张质钢, 王小虎, 杨克虎, 等.奈达铂联合5-氟尿嘧啶治疗晚期食管癌的Meta分析.中国循证医学杂志, 2013, 13(1):39-46.
18. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma:three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet, 2000, 355(9208):949-955.
19. Rinehart J, Ruff T, Cheung A, et al. Neo adjuvant and concomitant chemotherapy and radiation therapy in patients with advanced head and neck carcinoma. Otolaryngol Head Neck Surg, 2005, 132(1):69.
20. Ruggeri EM, Carlini P, Pollera CF, et al. Long term survival in locally advanced oral cavity cancer:an analysis of patients treated with neoadjuvant cisplat in-based chemotherapy followed by surgery. Head Neck, 2005, 27(6):452-458.
21. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemo radiation:a new treatment paradigm. J Clin Oncol, 2006, 24(4):593-598.
22. Guntinas-Lichius O, Appenrollts, Veelken F, et al. Phase Ⅱ study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope, 2006, 116(4):613-618.
23. Chu DT, Sham JS, Au GK, et al. A phase study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasophryngeal carcinoma. Oral Oncol, 2005, 41(6):589-595.
24. Francis PA, Kris MG, Rigas JR, et al. Paclitaxel(Taxol) and docetaxel(Taxotere):active chemotherapeutic agents in lung cancer. Lung Cancer, 1995, 12(1):163-172.
25. Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-Ⅱ trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol, 2001, 19(4):1096-1104.

Chinese Journal of Evidence-Based Medicine

Effectiveness of Taxanes Combined with Cisplatin and Fluorouracil for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content